Trial Profile
Open-Label, Single-Center, Phase 1 Clinical Trial to Evaluate the Safety and the Efficacy of NEUROTSTEM-AD in Patients With Dementia of the Alzheimer's Type
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Mesenchymal stem cell therapy (Primary)
- Indications Alzheimer's disease; Dementia
- Focus Adverse reactions
- 12 Oct 2012 New source identified (ClinicalTrials.gov: US National Institutes of Health, NCT01696591: Follow-up) and integrated.
- 12 Oct 2012 New source identified (ClinicalTrials.gov: US National Institutes of Health, NCT01696591: Follow-up) and integrated.
- 12 Oct 2012 New trial record